COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
2026 First Half Results: Strong Growth in Revenue, Profitability and Operating Free Cash Flow Full-year guidance confirmed
Vusion reports strong financial performance in H1 2026 with revenue growth of €820m in IFRS (+34%) and €839m on an adjusted basis (+29%). VAS revenue sees significant increase. EBITDA, EBIT, and net income show substantial growth. Operating free cash flow improves by 51%, ending with a net cash position of €197m. Full-year 2026 guidance confirmed -
-
-
-
COMMUNIQUÉ DE PRESSE
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Menarini Group and NewAmsterdam Pharma receive European Commission approval for Ubeslo and Evlarco, marking a milestone for cardiovascular disease treatment with LDL-C reduction therapies
![Logo de [UNKNOWN]](https://logos.symex.be/img/.jpg)
